{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Hoth Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"HOTH"},"Address":{"label":"Address","value":"1 ROCKEFELLER PLAZA,SUITE 1039, NEW YORK, New York, 10020, United States"},"Phone":{"label":"Phone","value":"+1 646 756-2997"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups."},"CompanyUrl":{"label":"Company Url","value":"https://www.hoththerapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Hayley Springer","title":"Vice President-Operations"},{"name":"Robbie Knie","title":"Chairman, President & Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}